P1, N=60, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2027 --> Jan 2026

P=N/A, N=400, Recruiting, Johns Hopkins University | Trial completion date: Dec 2026 --> Dec 2030 | Trial primary completion date: Aug 2026 --> Aug 2030

Dysgeusia began shortly after the initiation of mycophenolate mofetil (MMF) and led to reduced caloric intake, early satiety, and progressive sarcopenia...The overall clinical picture suggested that dysgeusia-associated malnutrition, likely exacerbated by medication exposure in the context of portal hypertension, contributed substantially to hepatic decompensation. This case underscores the overlooked impact of taste disturbances in cirrhotic patients and highlights the importance of early identification, medication review, and nutritional intervention to mitigate malnutrition-related complications.

Collectively, these findings identify CCL3 as a non-redundant effector of Breg-mediated protection, acting primarily through peripheral T-cell and myeloid remodeling, with secondary CNS impacts. These results highlight the translational potential of CCL3-competent, spleen-derived GIFT15 Bregs for therapeutic modulation of autoimmune demyelination.

P2, N=354, Recruiting, National Cancer Institute (NCI) | N=254 --> 354

P=N/A, N=1000, Recruiting, Sanofi

P=N/A, N=60, Recruiting, Waipapa Taumata Rau, the University of Auckland | Not yet recruiting --> Recruiting

We report the first documented case of myocarditis linked to the novel bifunctional PD-1/CTLA-4 combination, Iparomlimab and Tuvonralimab. This case highlights that structural drug optimizations do not preclude severe cardiotoxicity. In resource-limited settings lacking advanced imaging, serial high-sensitivity troponin monitoring served as the cornerstone for early detection and guiding management. This experience confirms that favorable outcomes are achievable through vigilant biomarker surveillance and coordinated multidisciplinary care, even without advanced diagnostics.

The patient was treated with prednisolone and mycophenolate mofetil, with close outpatient follow-up...This case highlights an atypical presentation of systemic scleroderma with band acro-osteolysis and dactylitis, emphasizing the importance of recognizing uncommon manifestations for early diagnosis and intervention. The multifactorial pathogenesis, involving vascular dysfunction and inflammation, underscores the need for personalized management to prevent complications.

P2, N=10, Recruiting, University of Chicago | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

For ribavirin, adenosine kinase (ADK) and adenylsuccinate synthase (ADSS) were critical for nucleotide metabolism and bioactivation. Remdesivir uptake and activation depended on the transporter SLC29A3 and phosphoamidase HINT1, whereas favipiravir resistance was linked to NT5C2-mediated dephosphorylation. Viral replication assays in Huh7 cells validated that knockout of SLC29A3, HINT1, or NT5C2 significantly altered antiviral efficacy. This study delineates the genetic network governing nucleotide analog response, providing mechanistic insights and potential biomarkers for personalized antiviral therapy.

In steroid-refractory or severe cases, adjunctive immunomodulators such as mycophenolate mofetil, janus kinase inhibitors, and notably abatacept are utilized, although evidence is largely case-based. By describing the management of three illustrative real-life cases, this article aims to provide a framework for individualized management of ICIrM in adults, integrating current guidelines, literature, and clinical experience. Continued research and prospective trials are critical to refine diagnostic algorithms and improve patient outcomes.